XNCR Shares Outstanding History



Below is a table of the XNCR shares outstanding history going back to 12/3/2013:

Date XNCR Shares Outstanding
12/3/201327.39M
3/14/201431.36M
4/30/201431.36M
7/24/201431.40M
11/6/201431.40M
2/6/201531.47M
4/24/201540.36M
7/24/201540.47M
10/28/201540.48M
2/26/201640.58M
4/26/201640.75M
7/28/201640.95M
10/25/201641.14M
2/17/201746.57M
5/2/201746.70M
8/1/201746.93M
10/31/201746.96M
2/16/201847.01M
5/4/201855.63M
8/1/201855.83M
10/31/201856.23M
2/15/201956.29M
5/2/201956.35M
8/1/201956.62M
7/22/201993.38M
10/31/201956.72M
2/14/202056.94M
4/29/202057.00M
7/30/202057.24M
10/30/202057.46M
2/16/202157.95M
4/26/202158.22M
7/28/202158.32M
11/1/202158.48M
2/16/202259.38M
4/29/202259.54M
7/29/202259.70M
11/3/202259.92M
2/15/202360.03M
4/29/202360.39M
7/28/202360.61M
11/1/202360.88M
2/15/202461.12M

Also see: XNCR Market Cap History
XNCR YTD Return
XNCR Historical Shares Outstanding:
+8.18% CAGR
XNCR Historical Shares Outstanding: +8.18% CAGR

Mouse over chart for data details
12/3/2013 ...2/15/2024
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells. We show 43 historical shares outstanding datapoints in our coverage of XNCR's shares outstanding history.

Understanding the changing numbers of XNCR shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like XNCR versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching XNCR by allowing them to research XNCR shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree XNCR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Xencor (XNCR) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

XOMA Shares Outstanding History
XON Shares Outstanding History
XRAY Shares Outstanding History
YMAB Shares Outstanding History
YMTX Shares Outstanding History
YTEN Shares Outstanding History
ZBH Shares Outstanding History
ZFGN Shares Outstanding History
ZGNX Shares Outstanding History
ZIMV Shares Outstanding History
More Healthcare companies »

 

XNCR Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.